Building Strategic Relationships with CROs

February 15, 2020

Shreekant Karmarkar, PhD, is president, DAT Pharma Consulting, Inc., skarmarkar@DATPharmaConsulting.com, 1-224-383-4493

BioPharm International, BioPharm International-02-15-2020, Volume 2020 eBook, Issue 1

Page Number: s20–s23

How to adopt win-win strategies and understand quality agreements for complying with cGMP when building strategic relationships with pharmaceutical contract research organizations.

Pharmaceutical and biopharmaceutical companies have been extensively using contract research organizations (CROs) to meet their challenging needs in R&D and standard work for several decades. A noticeable shift occurred in outsourcing research and clinical work when Big Pharma R&D costs skyrocketed. For example, in 2012, approximately 33% of drugs in the pipelines of the top 10 pharmaceutical companies were initially developed elsewhere (1).

Read this article in BioPharm International’s Outsourcing Resources February 2020 eBook.

Article Details

BioPharm International
Outsourcing Resources eBook
February 2020
Pages: s20–s23

Citation

When referring to this article, please cite it as S. Karmarkar, “Building Strategic Relationships with CROs,” in BioPharm International Outsourcing Resources eBook (February 2020).

Related Content:

| | | |